Retrospective, multicenter study analyzing the efficacy, durability, and tolerability of bictegravir/emtricitabine/ tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Therapeutic Use
Most Recent Events
- 16 Dec 2022 New trial record
- 26 Oct 2022 Results presented at the 16th International Congress on Drug Therapy and HIV Infection